Clinical trials: Lymphatic System Neoplasm
Lymphoma, Leukemia
Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507.
- Conditions
- Lymphoma, Leukemia, Cancer
- Trial name
- NCT00105313
- Testing
- MEDI-507
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- MedImmune LLC
Multiple Myeloma
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
This study tests the safety of a drug called SGN-CD352A, to find out what its side effects are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple myeloma.
- Trial name
- NCT02954796
- Testing
- SGN-CD352A
- Where
- 11 sites in United States
- Volunteers
- 27 people
- Sponsor
- Seagen Inc.
CD20-positive B-cell Non-Hodgkin Lymphoma
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
The purpose of this study is to identify if, and at what dose, ibrutinib may be administered with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and to document responses of this combination in…
- Trial name
- NCT01569750
- Testing
- Part 1, Cohort 1, Part 1, Cohort 2, Part 1, Cohort 3
- Where
- 7 sites in United States, France
- Volunteers
- 33 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Lymphocytic Leukemia
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to evaluate the safety and efficacy of NOX A12 in combination with a background therapy of bendamustine and rituximab (BR) chemotherapy in previously treated patients with chronic lymphocytic leukemia…
- Trial name
- NCT01486797
- Testing
- NOX-A12
- Where
- 17 sites in Austria, Belgium and 2 more
- Volunteers
- 28 people
- Sponsor
- TME Pharma AG
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]) and optimal dosing schedule(s) of JNJ-75348780 in participants with relapsed/ refractory B-cell Non-Hodgkin…
- Trial name
- NCT04540796
- Testing
- JNJ-75348780
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 147 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to evaluate the clinical efficacy and safety of Camidanlumab Tesirine (ADCT-301) in participants with relapsed or refractory Hodgkin Lymphoma (HL).
- Trial name
- NCT04052997
- Testing
- Camidanlumab Tesirine
- Where
- 73 sites in United States, Belgium and 9 more
- Volunteers
- 117 people
- Sponsor
- ADC Therapeutics S.A.
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
The purpose of this study is to provide the option of brentuximab vedotin treatment to eligible patients in studies SGN35-005 and C25001
- Conditions
- Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous
- Trial name
- NCT01196208
- Testing
- brentuximab vedotin
- Where
- 31 sites in United States, Australia and 13 more
- Sponsor
- Seagen Inc.
Colitis, Ulcerative
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
This is a study to understand if taking VTX002 daily as a tablet orally is safe and effective in participants diagnosed with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT05156125
- Testing
- VTX002
- Where
- 77 sites in United States, Bulgaria and 12 more
- Volunteers
- 213 people
- Sponsor
- Oppilan Pharma Ltd
Multiple Myeloma
Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma
This trial aims to evaluate the safety and efficacy of BCMA-CART in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT03492268
- Testing
- BCMA-CART
- Where
- China
- Sponsor
- Bioray Laboratories
Multiple Myeloma
A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
This was a multicenter, open-label, randomized phase II study which were to enroll 112 newly diagnosed symptomatic multiple myeloma patients in a 1:1 fashion.
- Trial name
- PANORAMA4 (NCT02720510)
- Testing
- Revlimid, Velcade, dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms, Non-Hodgkin Lymphoma
Study of TPI 287 in Patients With Advanced Malignancies
Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material.
- Conditions
- Neoplasms, Non-Hodgkin Lymphoma, Hodgkin Disease
- Trial name
- NCT00113724
- Testing
- TPI 287 Injection
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Cortice Biosciences, Inc.
Non-Hodgkin's Lymphoma, Lymphoma, B-Cell
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.
- Trial name
- NCT00061425
- Testing
- radiolabeled epratuzumab
- Sponsor
- Gilead Sciences
Lymphoma
Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these…
- Trial name
- NCT00460460
- Testing
- AZD4877
- Where
- 3 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
B-cell Lymphoid Malignancies
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies.
- Trial name
- NCT02569476
- Testing
- Zanubrutinib, Obinutuzumab
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 119 people
- Sponsor
- BeiGene
Chronic Lymphocytic Leukemia
Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia
The purpose of this study is to evaluate the safety of GCS-100 and the biologic activity of GCS-100 in subjects with chronic lymphocytic leukemia.
- Trial name
- PR-CS008 (NCT00514696)
- Testing
- GCS-100
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- La Jolla Pharmaceutical Company
Thrombocytopenia, Neutropenia
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
This research study will investigate the safety and effectiveness of two different dose levels of a new, unapproved drug to be given along with the chemotherapy regimens gemcitabine and carboplatin or gemcitabine and cisplatin…
- Conditions
- Thrombocytopenia, Neutropenia, Lymphopenia, Anemia
- Trial name
- NCT00771810
- Testing
- TXA127
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Tarix Pharmaceuticals
Multiple Myeloma
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
This is a phase I/II multicenter, open label, nonrandomized study for patients with Multiple Myeloma (MM) who will receive treatment with carfilzomib in place of bortezomib using the same bortezomib-containing combination regimen…
- Trial name
- NCT01365559
- Testing
- Group A: Carfilzomib & Non-IMiD Regimen, Group B: Carfilzomib & IMiD containing regimen.
- Where
- 9 sites in United States
- Volunteers
- 39 people
- Sponsor
- Oncotherapeutics
Leukemia, Chronic Myelogenous
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
The purpose of this Chinese bridging study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of asciminib versus best available therapy in Chinese patients with Chronic Myelogenous Leukemia in chronic phase…
- Trial name
- NCT04795427
- Testing
- asciminib, best available treatment
- Where
- 20 sites in China
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Lymphoma
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors and lymphomas.
- Trial name
- NCT03815682
- Testing
- Arm A: RPTR-147:1, Arm B: RPTR-147:1 and Pembrolizumab, Arm C: RPTR-147:2
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Repertoire Immune Medicines
Multiple Myeloma
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants…
- Trial name
- DREAMM 8 (NCT06956170)
- Testing
- Belantamab mafodotin, Pomalidomide, Dexamethasone
- Where
- 13 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.